Inhibitors in Chronic Myeloid Leukemia
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 20 February 2025 | Viewed by 4595
Special Issue Editors
Interests: leukemia
Special Issue Information
Dear Colleagues,
Chronic myeloid leukemia was identified as a chromosomal abnormality disease over 80 years ago in 1960. Targeted therapy, tyrosine kinase inhibitors, is the hallmark of chronic myeloid leukemia treatment. Patients could expect a comparable normal lifespan to the general people under the effective treatment strategies and patients who complete response to the medications. However, insights into the molecular mechanisms of pathogenesis, dealing with adverse events, therapeutic options for the patients in different disease stages and risk or for those without proper response to the available drugs, etc. still need deep understanding.
The aim of this special issue will focus on publishing high-quality works that are related to the understanding of the mechanisms of leukemogenesis, pathophysiology, diagnosis, and treatment of chronic myeloid leukemia with kinase or potential targets with inhibitors.
Prof. Dr. Robert Peter Gale
Prof. Dr. Qian Jiang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic myeloid leukemia
- pathogenesis
- diagnosis
- treatment
- inhibitor
- tyrosine-kinase inhibitor
- adverse events